Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-4-spiro-3'-pyrrolidine-1.2',3,5'-tetrone
2. As 3201
3. As-3201
4. Sx 3030
5. Sx 3202
6. Sx-3030
7. Sx-3202
1. 147254-64-6
2. As-3201
3. Ranirestat [inn]
4. Z26p56gftv
5. Chembl334830
6. (3r)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone
7. Sx-3030
8. (3r)-2'-(4-bromo-2-fluorobenzyl)spiro(pyrrolidine-3,4'(1'h)-pyrrolo(1,2-a)pyrazine)-1',2,3',5(2'h)-tetrone
9. (r)-2'-(4-bromo-2-fluorobenzyl)-1'h-spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5(2'h)-tetraone
10. Unii-z26p56gftv
11. C17h11brfn3o4
12. Raniestat
13. As 3201
14. Sx 3201
15. Ranirestat (jan/inn)
16. Ranirestat [jan]
17. Ranirestat [who-dd]
18. Schembl498993
19. Ranirestat, >=97% (hplc)
20. Dtxsid80163642
21. Zinc598422
22. Bcp14386
23. Bdbm50067407
24. Db05327
25. Sb17385
26. Sx-3201
27. Ncgc00484081-01
28. (r)-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-4-spiro-3'-pyrrolidine-1,2',3,5'-tetrone
29. 2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo(1,2-a)pyrazine-4-spiro-3'-pyrrolidine-1.2',3,5'-tetrone
30. Hy-15314
31. A13523
32. D06403
33. A901889
34. Q7293074
35. (3r)-2''-(4-bromo-2-fluorobenzyl)-1''h,2h,5h-spiro[pyrrolidine-3,4''-pyrrolo[1,2-a]pyrazine]-1'',2,3'',5(2''h)-tetrone
36. (3r)-2-(4-bromo-2-fluorobenzyl)spiro(pyrrolidine-3,4(1h)-pyrrolo(1,2-a)pyrazine)-1,2,3,5(2h)-tetrone
37. (r)-2-(4-bromo-2-fluorobenzyl)-1h-spiro[pyrrolidine-3,4-pyrrolo[1,2-a]pyrazine]-1,2,3,5(2h)-tetraone
38. Spiro(pyrrolidine-3,4'(1'h)-pyrrolo(1,2-a)pyrazine)-1',2,3',5(2'h)-tetrone, 2'-((4-bromo-2-fluorophenyl)methyl)-, (-)-
39. Spiro(pyrrolidine-3,4'(1'h)-pyrrolo(1,2-a)pyrazine)-1',2,3',5(2'h)-tetrone, 2'-((4-bromo-2-fluorophenyl)methyl)-, (3'r)-
| Molecular Weight | 420.2 g/mol |
|---|---|
| Molecular Formula | C17H11BrFN3O4 |
| XLogP3 | 1.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 2 |
| Exact Mass | 418.99170 g/mol |
| Monoisotopic Mass | 418.99170 g/mol |
| Topological Polar Surface Area | 88.5 Ų |
| Heavy Atom Count | 26 |
| Formal Charge | 0 |
| Complexity | 689 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Investigated for use/treatment in neuropathy (diabetic).
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
Ranirestat alleviates diabetic neuropathy, a complication of diabetes, by inhibiting aldose reductase and thereby inhibiting the accumulation of intracellular sorbitol that causes diabetic neuropathy. This drug has a stronger inhibitory effect and is longer acting compared to other drugs in this therapeutic area. Ranirestat showed good penetration into the nerve tissue, resulting in dose-dependent inhibition of intraneural accumulation of sorbitol and fructose in a clinical study.
ABOUT THIS PAGE
A Ranirestat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ranirestat, including repackagers and relabelers. The FDA regulates Ranirestat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ranirestat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ranirestat supplier is an individual or a company that provides Ranirestat active pharmaceutical ingredient (API) or Ranirestat finished formulations upon request. The Ranirestat suppliers may include Ranirestat API manufacturers, exporters, distributors and traders.
click here to find a list of Ranirestat suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Ranirestat DMF (Drug Master File) is a document detailing the whole manufacturing process of Ranirestat active pharmaceutical ingredient (API) in detail. Different forms of Ranirestat DMFs exist exist since differing nations have different regulations, such as Ranirestat USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Ranirestat DMF submitted to regulatory agencies in the US is known as a USDMF. Ranirestat USDMF includes data on Ranirestat's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Ranirestat USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Ranirestat suppliers with USDMF on PharmaCompass.
Ranirestat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ranirestat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ranirestat GMP manufacturer or Ranirestat GMP API supplier for your needs.
A Ranirestat CoA (Certificate of Analysis) is a formal document that attests to Ranirestat's compliance with Ranirestat specifications and serves as a tool for batch-level quality control.
Ranirestat CoA mostly includes findings from lab analyses of a specific batch. For each Ranirestat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ranirestat may be tested according to a variety of international standards, such as European Pharmacopoeia (Ranirestat EP), Ranirestat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ranirestat USP).
LOOKING FOR A SUPPLIER?
